OpportunityTitle: Elucidation of Mechanisms of Radiation-Induced Endovascular Injury and Development of Treatments / Mitigators for Radiation-Induced Endothelial Cell and Vascular Dysfunction (U01)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Description: The NIAID Radiation/Nuclear Countermeasures Development Program supports extramural research to develop safe and effective radiological/nuclear medical countermeasures for clinical use under emergency situations. This program spans basic through applied research. The role of the endovascular network in radiation injury pathogenesis is not well understood; however, the importance of this biological system in the observed multi-organ dysfunction and failure that occurs following radiation exposure has recently been established. The purpose of the Funding Opportunity Announcement (FOA) is to provide an opportunity for academic, industry and government laboratory researchers to address gaps in the understanding of the pathophysiology of radiation injury in the vasculature, and how this damage contributes to overall mortality following radiation exposure. This funding will also advance the development of post-exposure treatment approaches targeting the vascular endothelium, with the ultimate goal of licensure of candidate medical countermeasures by the Food and Drug Administration (FDA) for the radiation/nuclear public health emergency indication.
GrantorContactEmailDescription: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
GrantorContactText: NIH OER Webmaster&lt;br/&gt;FBOWebmaster@OD.NIH.GOV&lt;br/&gt;